Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK2 | O43353 | 3/20 | 0.42 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.31 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.31 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.30 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.30 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19947431 | 1.00 | RIPK2 (0.42) | RIPK2IRAK4CXCR3SMYD3KCNH2 | |
| SCHEMBL748003 | 0.82 | CHRNB2 (0.43) | IRAK4CXCR3CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL748002 | 0.82 | CHRNB2 (0.43) | IRAK4CXCR3CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL19947310 | 0.81 | RIPK2 (0.44) | RIPK2IRAK4CXCR3CHRNB2CHRNB4 | |
| SCHEMBL23501595 | 0.81 | KCNH2 (0.36) | SMYD3KCNH2CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL29934021 | 0.81 | KCNH2 (0.36) | SMYD3KCNH2CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL22574279 | 0.76 | SMYD3 (0.43) | SMYD3CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL19947447 | 0.75 | MAPK1 (0.42) | RIPK2SMYD3KCNH2 | |
| SCHEMBL29933947 | 0.75 | MAPK1 (0.42) | RIPK2SMYD3KCNH2 | |
| SCHEMBL3515522 | 0.73 | ALDH1A1 (0.41) | SMYD3KCNH2CHRNB2CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3512837-B1 | PYRIDINE AND PYRAZINE COMPOUNDS AS INHIBITORS OF RIPK2 | BOEHRINGER INGELHEIM INT (DE) | 2020-07-22 | — | — | EP | disclosed |
| US-10138222-B2 | Substituted benzamides as RIPK2 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-11-27 | — | — | US | disclosed |
| US-20180072703-A1 | PYRIDINE AND PYRAZINE COMPOUNDS AS INHIBITORS OF RIPK2 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10138222-B2 | Substituted benzamides as RIPK2 inhibitors | RIPK2, RIPK4, RIPK1 | RIPK2 1/4885IRAK4 41/4885CXCR3 1337/4885 |
| US-20180072703-A1 | PYRIDINE AND PYRAZINE COMPOUNDS AS INHIBITORS OF RIPK2 | RIPK2, RIPK1, RIPK4 | RIPK2 1/4885IRAK4 55/4885CXCR3 1201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.